The market for swine respiratory diseases treatment market is expected to grow at a CAGR of 7% during the forecast period of 2023 to 2030. It is generally accepted that pigs are the source of the infection which is referred to as swine respiratory disease. Some of its symptoms include a sore throat, fever, body aches, and various other symptoms. These symptoms are brought on as a result of the infection agents including mycoplasma hyopneumoniae and bordetellabronchiseptica as well as viral agents such as the respiratory syndrome (PRRS) virus. Other symptoms are brought on as a result of various other symptoms.
Pigs suffering from respiratory diseases have been the source of a significant amount of mortality as well as a financial burden for the swine industry. Swine respiratory infections, in particular, involve various infectious agents and have been one of the primary reasons for death in nursery pigs. Numerous preventative efforts, most notably the All-In–All-Out (AIAO) swine production system in the United States, have fallen short of meeting the aspirations of the swine sector with regard to profitability. Because of this, research on the aetiology of pneumonic swine's lungs has been given a boost, with mycoplasma hyopneumoniae being identified as the primary agent.
Additionally, in the next years, an increase in the investments made by government agencies for the treatment of veterinary diseases would further present prospective prospects for the expansion of the market for swine respiratory disease treatment. However, in the near future, the ability of pigs to naturally defend themselves against numerous pathogens might be an additional obstacle to the expansion of the market for swine respiratory illness treatments.
Rise In Consumption Of Pork Promotes Growth Of Swine Respiratory Diseases Treatment Market
The rise in the consumption of pork and the expansion of the pork industry are both major factors that are projected to promote the growth of the market for swine respiratory diseases treatment market. Also, the rapidly shifting patterns of disease are also projected to be a driving force behind the expansion of the market for the treatment of swine respiratory infections. It is expected that the increasing number of technological advancements associated with the production of pharmaceuticals would act as a further cushion for the expansion of the swine respiratory diseases treatment market. On the other hand, an increase in the choice of vegetarian food due to the risk of obesity is further predicted to restrict the expansion of the swine respiratory diseases treatment market during the course of the time period.
Investment In Large Pig Farms Will Increase Demand For Vaccines To Treat Swine Respiratory Diseases
Because of the increased amount of pork that is being produced, the market for treating swine respiratory illnesses is dominated by North America. Furthermore, pork farms are utilising vaccines as the pork sector is looking forward to producing pork that is disease free. This will further drive the growth of the swine respiratory diseases treatment market in the region throughout the time period that is being forecasted. It is anticipated that the market for the treatment of swine respiratory disorders will experience a substantial level of growth in Asia-Pacific as a result of an increase in the amount of investment that the government is making in the pig sector in order to promote large pig farms. In addition, it is projected that the rise in the expansion of the animal sector, which employs millions of people, would further fuel the growth of the swine respiratory diseases treatment market in the region in the years to come.
Spread Of Porcine Reproductive And Respiratory Syndrome Will Increase Market Growth Of Drugs For Treatment
Porcine Reproductive and Respiratory Syndrome (PRRS), which is one of the most prevalent diseases, primarily affects pigs' respiratory systems and is one of the most common respiratory disorders. A virus is responsible for causing Porcine Respiratory and Reproductive Syndrome, and this virus falls under the category of arterivirus. The condition known as PRRS is also referred to as blue-ear pig sickness. The Porcine Reproductive and Respiratory Syndrome (PRRS), commonly known as the mysterious swine sickness, was discovered in the United States in the 1980s. The PRRS disease is fast spreading throughout all of the countries that are involved in the production of pigs; at this point, there are only a very small number of countries that are PRRS-free. The consumption of pork is growing over the years in every location, which immediately encourages the pork industry to produce more pork that is free of disease. This increases the pork industry's capacity to satisfy the growing demand for pork on the worldwide market.
Production Of Pork In North America Is Increasing
The production of pork in North America is increasing as a direct response to the growing demand for pork in nations like the United States and Canada. Pork, which is free of pathogens is making a direct contribution to meeting the demand in the meat business. The vast majority of pig farms in the pork industry in North America, particularly in the United States, are now using vaccines. This is because the pork industry is working towards the goal of producing meat that is disease free. The primary purpose of vaccination is to act as a preventative measure against the infection caused by dangerous pathogens. It is becoming more common practice to administer vaccinations against porcine reproductive and respiratory syndrome (PRRS) and mycoplasma. The vaccine is administered directly to breeding females in order to ensure that the offspring are free of pathogens. Because of rising rates of vaccination, the market in North America is expected to be a large and dominant market. In addition, the market is fairly favorable for investors in the animal healthcare sector.
Increased Investment In The Research For Effective Treatment Of Swine Respiratory Diseases
Research into the etiology of porcine reproductive and respiratory illness has been sponsored by a number of pharmaceutical corporations. The treatment of swine respiratory infections has been given a significant boost as a result of this. They appear to be focusing more and more on infectious disorders, which has resulted in an expansion of our understanding of main respiratory infectious agents, which include viruses in addition to bacteria.
Research on pigs' defense systems has been sparked as a result of growing awareness about the health of pigs among pork consumers. This has, in turn, encouraged the expansion of the market for treatments for respiratory disorders in pigs. The pig reproductive and respiratory syndrome virus (PRRSV), the swine influenza virus, and porcine circovirus type 2 are the principal pathogens that are being investigated at this time. A significant amount of research has been conducted with the goal of determining the prevalence of PRRSV in swine herds in a variety of nations. The increasing application of DNA metagenomic analysis technologies has been one factor that has contributed to the market for swine respiratory diseases therapy maintaining its rapid rate of development.
Increasing Awareness Towards Animal Healthcare Will Expand The Market
The market for the treatment of swine diseases is expected to experience substantial expansion as a result of increasing awareness regarding animal health, early disease identification, and preventative treatments. The growing incidence of diseases like swine influenza and porcine parvovirus will lead to an increase in the need for treatment of swine diseases in the global market. As a result of the preventative nature of veterinary healthcare, it is anticipated that the market for the treatment of swine diseases would experience significant growth over the course of the projected period.
The market for swine illnesses treatments across the globe is being pushed forward by reasons such as the rapidly shifting disease patterns among animals. The market for the treatment of swine diseases will expand as a result of technological advancements, as well as an increase in the manufacturing of pharmaceuticals and vaccinations.
The development in people's awareness of the importance of animal health and the increase in spending by governmental entities on veterinary care are both factors that will contribute to the expansion of the swine disease treatment market. The market for the treatment of swine diseases is expected to experience significant expansion as a result of the rising incidence of porcine diseases such as swine influenza.
Challenges To The Growth Of Swine Respiratory Disease Treatment Market
The growth of the swine disease treatment market would be hampered by factors such as the sluggish economy and rising costs associated with the storage and maintenance of vaccines. The rising popularity of vegetarian cuisine, which can be attributed to the increasing danger of obesity caused by the intake of food produced by livestock, will also slow down the expansion of the market for treatments for swine diseases.
Also, severe regulatory guidelines that restrict the use of medications in swine are expected to be a factor that slows the growth of the global swine healthcare market. For example, in April of 2016, the Center for Veterinary Medicine (CVM) division of the United States Food and Drug Administration (FDA) initiated steps to withdraw carbadox drug from use in swine due to the presence of a trace amount of carcinogenic residue in pork meat. This was done because the drug was found to cause cancer in humans.
Mycoplasma-Based Causative Agents Dominated the Market In 2021
Mycoplasma-based causative agents are projected to exhibit strong growth, with a compound annual growth rate (CAGR) of 6% during the forecast period. These agents currently hold a market share of around 35% in the overall market. Mycoplasma hyopneumoniae is the primary causative agent of enzootic pneumonia, a persistent respiratory condition that can be found in pigs. Infections brought on by M. hyopneumoniae are rather widespread in virtually all of the places in which swine production takes place. These infections result in significant economic losses as a result of higher medication consumption and decreased pig performance.
Pharmaceutical Segment Clearly Owned Over 60% of the Revenue in 2021
With a current market share of approximately 62% in 2021, the pharmaceuticals category is predicted to offer rapid growth at a CAGR of 6% by the end of the forecast period, which will bring the total market share to an all-time high. The use of antibiotics during all stages of growth improves the efficiency and effectiveness of body weight gain, lowers death rates and comorbidities, reduces the prevalence of subclinical disease, and increases the overall health of pigs.
Oral Mode of Administration Clearly Dominated the Market with Market Share of Over 85%
By the conclusion of the forecast period, oral-based modes of administration are anticipated to offer rapid growth at a CAGR of 6.3%, having a market share of approximately 85% in the global market in 2021. In most cases, medication is given to farm animals through the digestive system, often known as the oral mode of administration. To make it simpler for the animals to consume the medicine, it is typically included with their food.
Veterinary Hospitals to Dominate Among Other Channels of Distribution
Because pigs are better subjects for medical research than mice due to their size, physiology, and genetic makeup being more similar to humans, veterinary hospitals are expected to hold the highest market share value of 35.0% during the year 2021. This is due to the fact that pigs are larger than mice, which makes them easier to study.
APEJ To Dominate the Market for Swine Respiratory Disorder
It is anticipated that APEJ would dominate the market for the treatment of swine respiratory disorders. However, it is in competition with Eastern Europe, which is now in the lead in terms of CAGR during the forecasted period. One of the industries that is expanding at the quickest rate throughout the majority of Asia Pacific's nations is the animal business. It is a vital industry that is connected to millions of jobs in industries that are tied to it. On the other hand, the appearance of new animal diseases poses a risk to both the health and expansion of this sector of the economy. The APEJ market includes China's pig industry, in which the Chinese government is eager to invest and expand the pig industry by increasing support for large-scale pig farmers through the implementation of supportive policies.
US Is Expected to Command A Significant Share Of The Swine Respiratory Diseases Treatment Market
Due to the presence of a well-established swine industry as well as the rising incidence of swine infections such as Swine Enteric Coronavirus Diseases (SECD), porcine epidemic diarrhoea (PEDv), and porcine delta coronavirus (PDCoV), which cause significant morbidity and mortality, particularly in young piglets, North America is expected to dominate the market. The expansion of the market that was analyzed in the region is being jointly driven by all of these different variables.
In the market for swine healthcare, it is anticipated that the United States will have a significant portion of the market share in the North American area. The United States has been either the world's largest or second-largest exporter of pork and pig products in recent years, with exports averaging over 20% of commercial pork output in most years. As the prevalence of different diseases affecting pigs continues to rise, it is projected that there will be a greater need over time for items relating to the healthcare of pigs in order to sustain the expansion of the pig farming business. A number of the programs that are conducted by the government of the United States give money for the research and development of therapies for swine diseases. It is anticipated that this will further contribute to the expansion of the market in the United States.
Market to Remain Fragmented and Strategic Collaborations to Provide Competitive Advantage
The overall market is fragmented due to the presence of various competitors operating in the production sector of treatments for swine respiratory illnesses. These businesses are pursuing strategies such as mergers and acquisitions, partnerships and collaborations, and the introduction of new products in order to satisfy the demand of their customers and increase the size of their existing customer base. The following are some examples of significant development strategies employed by industry firms operating in the market for treatments for respiratory disorders affecting pigs:
AROVYNTM (tulathromycin injection) and NUFLOR®-S (florfenicol injectable solution) are two broad-spectrum, prescription antibiotics that are used to treat the primary pathogens that are linked to swine respiratory disease (SRD). In March 2023, Merck Animal Health, which is also known as MSD Animal Health outside of the United States and Canada, announced that these two antibiotics had been approved by the United States Food and Drug Administration (FDA).
In September of 2021, Invetx and Boehringer Ingelheim made public their intention to work together on the research, development, and eventual sale of novel veterinary pharmaceuticals.
Key players operating in the swine respiratory disease treatment market include Zoetis, Inc. Merck Animal Health, Bayer AG, Boehringer Ingelheim Vetmedica, Inc., Elanco Animal Health, Virbac Group, Norbrook, CevaSantéAnimale, Vetoquinol, Bimeda holdings PLC, and Agrilabs, Inc.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Swine Respiratory Diseases Treatment market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Causative agent
| |
Treatment
| |
Route Of Administration
| |
Distribution Channel
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
